A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Quadramet Patient, Information, Instructions - Samarium SM 153 Lexidronam
Quadramet Patient, Information, Instructions - Samarium SM 153 Lexidronam
PATIENT INFORMATION
Patients who receive Quadramet should be advised that for several
hours following administration, radioactivity will be present in excreted urine.
To help protect themselves and others in their environment, precautions need
to be taken for 12 hours following administration. Whenever possible, a toilet
should be used, rather than a urinal, and the toilet should be flushed several
times after each use. Spilled urine should be cleaned up completely and patients
should wash their hands thoroughly. If blood or urine gets onto clothing, the
clothing should be washed separately, or stored for 1-2 weeks to allow for decay
of the Sm-153.
Some patients have reported a transient increase in bone pain
shortly after injection (flare reaction). This is usually mild and self-limiting
and occurs within 72 hours of injection. Such reactions are usually responsive
to analgesics.
Patients who respond to Quadramet might begin to notice the
onset of pain relief one week after Quadramet. Maximal pain relief generally
occurs at 3-4 weeks after injection of Quadramet. Patients who experience a
reduction in pain may be encouraged to decrease their use of opioid analgesics.
Laboratory Tests: Because of the potential for bone
marrow suppression, beginning 2 weeks after Quadramet administration, blood
counts should be monitored weekly for at least 8 weeks, or until recovery of
adequate bone marrow function.
In a subset of 31 patients who had serum calcium monitored
during the first 2 hours after Quadramet infusion, a clear pattern of calcium
change was not identified. However, 10 (32%) patients had at least one serum
calcium level that was below normal (7.16 to 8.28). The extent to which samarium-153-EDTMP
is related to this hypocalcemia is not known. Caution should be exercised when
administering Quadramet to patients at risk for developing hypocalcemia.
Please also see the WARNINGS
and PRECAUTIONS sections.
top
